Home > Result Summaries: Compounds > ibandronic acid Result Summaries: ibandronic acid GSKStudy ID Phase Title Summary (Download) 109393 Phase 4 An open-label, multi-centre, randomized study to investigate patient preference on dosing in the once-monthly ibandronate and the once-weekly risedronate in Korean women with postmenopausal osteoporosis. A six-month, two-sequence, and two period crossover study (0 citation(s)) 110603 phase 4 An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of BONVIVA(ibandronate) administered in Korean patients according to the prescribing information (0 citation(s)) 112437 phase 4 Osteoporosis: GPRD study - An assessment of GI associated adverse events associated with bisphophonates in the UK (0 citation(s)) 743830/002 Phase 1 An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate (0 citation(s)) 743830/003 Phase 1 An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate (0 citation(s)) BON103593 Phase 4 A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis (0 citation(s)) IBN104125 phase 3 See Detailed Description (0 citation(s))
